Evidence map›Paper›PMID 28681218›Full record

Trial reportMedical oncology (Northwood, London, England)2017

Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study.

Maki Tanioka, Satoshi Yamaguchi, Muneaki Shimada, Shoji Nagao, Kazuhiro Takehara, Masato Nishimura, Satoshi Morita, Shunichi Negoro, Kiyoshi Fujiwara, Junzo Kigawa

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Maki TaniokaDepartment of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi, Hyogo, 673-8558, Japan. makitanioka123456@yahoo.co.jp.ORCID http://orcid.org/0000-0002-6558-2246
Satoshi YamaguchiGynecologic Oncology, Hyogo Cancer Center, Akashi, Japan.
Muneaki ShimadaGynecologic Oncology Division, Tohoku University Hospital, Sendai, Japan.
Shoji NagaoGynecologic Oncology, Saitama University International Medical Center, Hidaka, Japan.
Kazuhiro TakeharaObstetrics and Gynecology, Kure Medical Center/Chugoku Cancer Center, Kure, Japan.
Masato NishimuraObstetrics and Gynecology, School of Medicine University of Tokushima, Tokushima, Japan.
Satoshi MoritaBiomedical Statistics and Bioinformatics, Kyoto University, Kyoto, Japan.
Shunichi NegoroDepartment of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi, Hyogo, 673-8558, Japan.
Kiyoshi FujiwaraGynecologic Oncology, Hyogo Cancer Center, Akashi, Japan.
Junzo KigawaGynecologic Oncology Division, Tottori University Hospital, Yonago, Japan.
Hyogo Prefectural Cancer Center · JPKure Medical Center · JPKyoto University · JPTohoku University Hospital · JPTokushima University · JPTottori University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study is to evaluate the outcome and safety of the multidisciplinary strategy using cisplatin plus dose-dense paclitaxel (dose-dense TP) before and after radical hysterectomy (RH) for stage IB2, IIA2, or IIB patients with cervical cancer. In the dose-finding phase, 12 patients received 3 cycles of cisplatin (75 mg/m

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinDisease-Free SurvivalDose-Response Relationship, DrugFemaleHumansHysterectomyMiddle AgedNauseaNeutropeniaPaclitaxelTreatment OutcomeUterine Cervical NeoplasmsCisplatinPaclitaxelCervical cancerCisplatinDose densePaclitaxelPathological complete responsePhase II

Identifiers

PMID28681218
OpenAlexW2724552327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.